8-K: Amedisys Extends Credit Facility Maturity and Reports Q1 2025 Financial Results

Amedisys extends its credit facility maturity to July 2027 and reports increased net service revenue and adjusted EBITDA for the first quarter of 2025.

Summary

• Amedisys, Inc. entered into a Fourth Amendment to its Amended and Restated Credit Agreement, extending the maturity date of the credit facility from July 30, 2026, to July 30, 2027.
• The amendment also includes provisions for Outbound Investment Rules related to regulations administered by the U.S. Treasury Department under Executive Order 14105.
• For the three-month period ended March 31, 2025, net service revenue increased to $594.8 million from $571.4 million in 2024.
• Net income attributable to Amedisys, Inc. was $61.0 million, compared to $14.4 million in 2024, inclusive of merger-related expenses and a gain on an equity method investment.
• Adjusted EBITDA for the quarter was $68.8 million, compared to $59.9 million in 2024.
• Adjusted net income attributable to Amedisys, Inc. was $41.6 million, compared to $33.9 million in 2024.
• The company will not hold a quarterly earnings call due to the pending merger with UnitedHealth Group Incorporated.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the extension of the credit facility and improved financial results, but tempered by the pending merger and associated uncertainties.

Positives

• The extension of the credit facility provides Amedisys with continued financial flexibility.
• The increase in net service revenue and adjusted EBITDA indicates improved financial performance.
• The company maintains a 4-Star average in the Jan 2025 HHC Final release with 88% of our providers (representing 88% of care centers) at 4+ Stars and 46% of our providers (representing 42% of care centers) at 4.5+ Stars.
• Amedisys maintains industry leading quality scores.

Negatives

• Merger-related expenses impacted net income.
• Operating cash flow was negative at $(3.7)M.
• Free cash flow was negative at $(14.6)M.
• Days sales outstanding (DSO) increased to 45.7 from 43.0 in the previous quarter.

Risks

• The pending merger with UnitedHealth Group could cause disruption to patient, payor, provider, referral source, supplier, or management and employee relationships.
• Regulatory approvals for the proposed merger may be delayed or not obtained.
• The company faces risks related to changes in Medicare and other medical payment levels.
• Staffing shortages driven by the competitive labor market could impact operations.
• The company's ability to integrate, manage and keep its information systems secure is a risk.
• Uncertainty around, and disruption from, new and emerging technologies, including the adoption and utilization of artificial intelligence ('AI') and generative AI and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Future Outlook

Due to the pending merger with UnitedHealth Group, Amedisys will not conduct a quarterly earnings call.

Industry Context

The home health and hospice industry is experiencing regulatory changes, as reflected in the reimbursement rule updates. Amedisys is positioning itself to navigate these changes while continuing to provide quality care.

Comparison to Industry Standards

• Amedisys's Quality of Patient Care (QPC) scores are above the industry average.
• Amedisys maintains a 4-Star average in the Jan 2025 HHC Final release with 88% of our providers (representing 88% of care centers) at 4+ Stars and 46% of our providers (representing 42% of care centers) at 4.5+ Stars.
• Amedisys's Patient Satisfaction scores are above the industry average.

Stakeholder Impact

• Shareholders may be impacted by the pending merger with UnitedHealth Group.
• Employees may experience uncertainty due to the merger.
• Patients should continue to receive high-quality care.
• Payors will be impacted by changes in reimbursement rates.

Key Dates

Keywords

Amedisys, credit facility, financial results, home health, hospice, EBITDA, merger, UnitedHealth Group, revenue, healthcare